Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Learn more about Tempus Next. Chris Scotto DiVetta, SVP of Applications at Tempus AI introduces Tempus Next, an AI enabled care pathway platform that helps providers accelerate …

Feb 1, 2023 · We’ve built a variety of these AI-driven algorithms at Tempus. Our Tempus|TO (or tumor origin) test uses RNA expression results from tumor metastases to predict the patient’s …

With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, …

Sep 12, 2024 · Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a …

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s …

Nov 4, 2024 · Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with …

Jan 13, 2025 · CHICAGO--(BUSINESS WIRE)--Jan. 13, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient …

Sep 4, 2024 · BioNTech will work collaboratively with Tempus to leverage Tempus’ real-world multimodal database to generate novel insights into the biological mechanisms supporting the …

Jul 16, 2024 · Tempus’ AI-enabled platform generates the type of rich multimodal data required to develop a novel class of predictive algorithms that can be introduced in the clinic to support …